These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24834924)

  • 1. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab.
    Prazma CM; Wenzel S; Barnes N; Douglass JA; Hartley BF; Ortega H
    Thorax; 2014 Dec; 69(12):1141-2. PubMed ID: 24834924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways.
    Cataldo D; Louis R; Michils A; Peché R; Pilette C; Schleich F; Ninane V; Hanon S
    J Asthma; 2021 Apr; 58(4):448-458. PubMed ID: 31928102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients.
    Richards LB; van Bragt JJMH; Aarab R; Longo C; Neerincx AH; Sont JK; Weersink EJM; Braunstahl GJ; Brinke AT; Bel EHD; Maitland-van der Zee AH
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):2999-3008.e1. PubMed ID: 32344189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
    Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
    Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.
    d'Ancona G; Kavanagh J; Roxas C; Green L; Fernandes M; Thomson L; Dhariwal J; Nanzer AM; Jackson DJ; Kent BD
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32060061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
    Yancey SW; Bradford ES; Keene ON
    Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 17. Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma.
    Nguyen VQ; Ulrik CS
    Allergy Asthma Proc; 2016 Nov; 37(6):125-139. PubMed ID: 27931289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation Rate Reduction With Mepolizumab Stratified by Maintenance Oral Corticosteroids Use and Eosinophil Levels: A Post Hoc Analysis of the DREAM and MENSA Studies.
    Bobolea I; Bañas D; Melero C; de Andrés AI; Joksaite S; Sánchez-Herrero G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):148-150. PubMed ID: 34085935
    [No Abstract]   [Full Text] [Related]  

  • 19. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
    Bourdin A; Shaw D; Menzies-Gow A; FitzGerald JM; Bleecker ER; Busse WW; Ferguson GT; Brooks L; Barker P; Gil EG; Martin UJ
    J Asthma; 2021 Apr; 58(4):514-522. PubMed ID: 31859541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.